Analysis of factors influencing tacrolimus levels and immunoassay bias in renal transplantation

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 1035-1042

  Borrows, Richard ^a,b   Chusney, Gary ^a   Loucaidou, Marina ^a   James, Anthony ^a   Goel, Shruti ^a   Borrows, Sarah ^a   Van Tromp, Jen ^a   Cairns, Tom ^a   Griffith, Megan ^a   Hakim, Nadey ^a   McLean, Adam ^a   Palmer, Andrew ^a   Papalois, Vassilios ^a   Taube, David ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Renal transplantation; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MONITORING; FACTORIAL ANALYSIS; FEMALE; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PATIENT MONITORING; STATISTICAL SIGNIFICANCE;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MASS SPECTROMETRY; TACROLIMUS;

EID: 34447621005     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007303765     Document Type: Article

References (49)

1. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005 ; 331: 810.
2. Bottiger Y., Brattstrom C., Tyden G., et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1999 ; 48: 445-448.
3. Kershner RP, Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996 ; 62: 920-926.
4. Laskow DA, Vincenti F., Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996 ; 62: 900-905.
5. Staatz C., Taylor P., Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001 ; 16: 1905 -1909.
6. Kuypers DR, Claes K., Evenepoel P., et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004 ; 75: 434-447.
7. Mourad M., Malaise J., Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001 ; 47: 1241-1248.
8. Undre NA, van Hooff J., Christiaans M., et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999 ; 31: 296-298.
9. Jusko WJ, Thomson AW, Fung J., et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995 ; 17: 606-614.
10. Murthy JN, Davis DL, Yatscoff RW, et al. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem. 1998 ; 31: 613-617.
11. Homma M., Tomita T., Yuzawa K., et al. False positive blood tacrolimus concentration in microparticle enzyme immunoassay. Biol Pharm Bull. 2002 ; 25: 1119-1120.
12. Akbas SH, Ozdem S., Caglar S., et al. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. Clin Biochem. 2005 ; 38: 552-557.
13. Tomita T., Homma M., Yuzawa K., et al. Effects of hematocrit value on microparticle enzyme immunoassay of tacrolimus concentration in therapeutic drug monitoring. Ther Drug Monit. 2005 ; 27: 94-97.
14. Brown NW, Gonde CE, Adams JE, Tredger JM Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. Clin Chem. 2005 ; 51: 586-592.
15. Michalska C., Shiferaw E., Johnston A., Holt D. Measurement of tacrolimus. does the choice of anticoagulant matter [abstract]. Ther Drug Monit. 2005 ; 27: 222.
16. Borrows R., Chusney G., Loucaidou M., et al. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus. Ther Drug Monit. 2006 ; 28: 269-273.
17. Staatz CE, Willis C., Taylor PJ, Tett SE Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002 ; 72: 660-669.
18. Staatz CE, Tett SE Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004 ; 43: 623-653.
19. Kuypers Drj, Claes K., Evenepoel P., et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004 ; 43: 741-762.
20. van Duijnhoven EM, Boots JM, Christiaans MH, et al. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int. 2003 ; 16: 721-725.
21. Lemahieu WP, Maes BD, Vanrenterghem Y. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. Transplant Proc. 2005 ; 37: 2051-2053.
22. Keevil BG, McCann SJ, Cooper DP, Morris MR Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2002 ; 39: 487-492.
23. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16: 31-41.
24. Moran SM, Myers BD Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 1985 ; 27: 928-937.
25. Maes BD, Dalle I., Geboes K., et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation. 2003 ; 75: 665-672.
26. van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002 ; 25: 707-712.
27. Goldstein H. Multilevel Statistical Models. 3 rd ed. London: Edward Arnold, and New York: Wiley ; 2003.
28. Altman DG Subgroup analyses. In: Practical Statistics for Medical Research. London: Chapman and Hall ; 1991: 466-467.
29. Gruber SA, Hewitt JM, Sorenson AL, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol. 1994 ; 34: 859-864.
30. Saeki T., Ueda K., Tanigawara Y., et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 ; 268: 6077-6080.
31. Huang Z., Murakami T., Okochi A., et al. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol. 2000 ; 406: 453-460.
32. Okabe H., Yano I., Hashimoto Y., et al. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J Pharm Pharmacol. 2002 ; 54: 65-70.
33. Venkataramanan R., Swaminathan A., Prasad T., et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995 ; 29: 404-430.
34. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 ; 23: 247-255.
35. Machado CG, Calado RT, Garcia AB, et al. Age-related changes of the multidrug resistance p-glycoprotein function in normal human peripheral blood T-lymphocytes. Bras J Med Biol Res. 2003 ; 36: 1653-1657.
36. Bekersky I., Dressler D., Mekki QA Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol. 2001 ; 41: 176-182.
37. Napoli KL Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients. Ther Drug Monit. 2006 ; 28: 491-504.
38. Zahir H., McCaughan G., Gleeson M., et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004 ; 57: 298-309.
39. Shimada T., Terada A., Yokogawa K., et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002 ; 74: 1419-1424.
40. Lampen A., Christians U., Gonschior AK, et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol. 1996 ; 117: 1730-1734.
41. Yasuda K., Lan L-B., Sanglard D., et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 ; 303: 323-332.
42. Wu CY, Benet LZ Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos. 2003 ; 31: 1292-1295.
43. Ito T., Yano I., Tanaka K., et al. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 ; 282: 955-960.
44. Federico S., Carrano R., Capone D., et al. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet. 2006 ; 45: 169-175.
45. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004 ; 78: 557-565.
46. Benet LZ, Cummins CL, Wu CY Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab. 2003 ; 4: 393-398.
47. Papadimitriou JC, Cangro CB, Lustberg A., et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol. 2003 ; 11: 295-302.
48. Lemahieu Wpd, Maes BD, Verbeke K., et al. Combination of CyP3A4 measurement in vivo and genetic stratification for p-glycoprotein explains 71% of the variability of dose/weight normalised Tacrolimus trough levels in renal transplant recipients [abstract]. Am J Transplant. 2005 ; 5 (suppl 11). 390-391.
49. Wu CY, Benet LZ Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005 ; 22: 11-23.